Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2018

View Archived Issues

MedImmune initiates phase I study of MEDI-6570

89Bio launches to develop drug for NASH

France becomes first country to market baclofen preparation to reduce alcohol consumption

Boehringer Ingelheim initiates phase I study of BI-730460

Uniparental mice give insights into ESC imprinting

Dual ICOS/CD28 antagonist demonstrates efficacy in models of autoimmune disease

Single locus near SIM1 gene significantly associated with risk of erectile dysfunction

OT-1096, a novel immunoactivating molecule that shows efficacy in xenograft models of TNBC

Phase I U.S. data presented for KN-035 in patients with advanced solid tumors

Pfizer and Novartis collaborate to study NASH therapy combinations

ASP-5094 safe and well tolerated in patients with rheumatoid arthritis on methotrexate

Griffithsin intravaginal gel well tolerated in first-in-human trial

Opthea reports promising 12-week data from phase Ib study of OPT-302 in DME

Novo Nordisk reports PIONEER 8 topline results with oral semaglutide in type 2 diabetes

Phase II data presented for SEL-212 in symptomatic gout patients

Novartis reports year 2 data from brolucizumab phase III trials in wet AMD

Genentech presents data on faricimab and ranibizumab PDS in wet AMD

Aduro initiates phase I study of ADU-1604 in metastatic melanoma

New phase I trial evaluates TAK-981 in metastatic solid tumors or lymphomas

Qrumpharma develops inhaled agent for nontuberculous mycobacterial infections

Innovate demonstrates preclinical proof of concept for larazotide in NASH mouse model

New phase Ib/IIa study explores use of AG-019 for treatment of early-onset type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...